LYBALVI Trademark

Trademark Overview

On Wednesday, November 29, 2017, a trademark application was filed for LYBALVI with the United States Patent and Trademark Office. The USPTO has given the LYBALVI trademark a serial number of 87700839. The federal status of this trademark filing is REGISTERED as of Tuesday, July 20, 2021. This trademark is owned by Alkermes Pharma Ireland Limited. The LYBALVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
lybalvi

General Information

Serial Number87700839
Word MarkLYBALVI
Filing DateWednesday, November 29, 2017
Status700 - REGISTERED
Status DateTuesday, July 20, 2021
Registration Number6428572
Registration DateTuesday, July 20, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 24, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 8, 2017
Primary Code005
First Use Anywhere DateMonday, April 19, 2021
First Use In Commerce DateMonday, April 19, 2021

Trademark Owner History

Party NameAlkermes Pharma Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDublin
IE
Party NameAlkermes Pharma Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDublin
IE
Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin
IE

Trademark Events

Event DateEvent Description
Saturday, December 2, 2017NEW APPLICATION ENTERED
Friday, December 8, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 13, 2018ASSIGNED TO EXAMINER
Thursday, March 15, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 4, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 24, 2018PUBLISHED FOR OPPOSITION
Tuesday, April 24, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 19, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 10, 2018SOU TEAS EXTENSION RECEIVED
Monday, December 10, 2018SOU EXTENSION 1 FILED
Monday, December 10, 2018SOU EXTENSION 1 GRANTED
Wednesday, December 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 31, 2019SOU TEAS EXTENSION RECEIVED
Friday, May 31, 2019SOU EXTENSION 2 FILED
Friday, May 31, 2019SOU EXTENSION 2 GRANTED
Tuesday, June 4, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 8, 2019SOU TEAS EXTENSION RECEIVED
Friday, November 8, 2019SOU EXTENSION 3 FILED
Friday, November 8, 2019SOU EXTENSION 3 GRANTED
Tuesday, November 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 7, 2020SOU TEAS EXTENSION RECEIVED
Thursday, May 7, 2020SOU EXTENSION 4 FILED
Thursday, May 7, 2020SOU EXTENSION 4 GRANTED
Saturday, May 9, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 29, 2020SOU TEAS EXTENSION RECEIVED
Monday, November 9, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 29, 2020SOU EXTENSION 5 FILED
Monday, November 9, 2020SOU EXTENSION 5 GRANTED
Tuesday, November 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 22, 2021TEAS STATEMENT OF USE RECEIVED
Thursday, April 22, 2021USE AMENDMENT FILED
Monday, April 26, 2021STATEMENT OF USE PROCESSING COMPLETE
Monday, May 17, 2021SU - NON-FINAL ACTION - WRITTEN
Monday, May 17, 2021NON-FINAL ACTION E-MAILED
Monday, May 17, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 16, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, June 17, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, July 20, 2021REGISTERED-PRINCIPAL REGISTER
Friday, April 24, 2026ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

Related Keywords

lybalvi treatment depression bipolar diseases disorder pharmaceutical preparations resistant gain dyslipidemia